Aktuelles_Headerbild2 klein






Quality Management of Limedion

Already last year, Dr. Kovacs successfully completed the training course of several months to become a Regulatory Affairs Manager. The following topics were taught and tested in two final exams:

- Technical documentation according to EU MDR - structure and content,
- Risk management - contents and requirements of ISO 14971,
- Biocompatibility and biological safety of medical devices,
- Clinical evaluation and clinical testing of medical devices,
- The usability process for medical device manufacturers - methods and documentation,
- Approval procedures for medical devices in the USA, China, Japan, Taiwan, Brazil, Mexico, Argentina, Malaysia, Singapore (ASEAN), Australia, South Korea, Russia and Saudi Arabia.

In addition, Mr. Benner attended a further education to become a quality management representative (QMR), whereupon from now on he will take over the activity as QMR in our company.

Regulatory Affairs Manager - Zertifikat





New Homepage

On the first of February we have uploaded a freshly homepage. It has not only a completely new layout, but now also offers information about current news in the company and updates about the current funding project "Z-Bioresorb".


Limedion has a new homepage!





Magentron sputtering

Due to a customer request, in which heating and cooling of the substrates during the coating process was necessary, we were able to expand our range in the area of magnetron sputtering with a target heating and cooling on a ceramic basis.





Z-Bioresorb-Sponsorhip project

In September 2020, the companies Limedion and Quadralux have started a BMBF-funded project: Z-Bioresorb. This project investigates the possibility of using zinc as a novel implant material. Zinc offers the advantage that it dissolves in the body after a certain time without producing harmful by-products. On November 17, a meeting with the project sponsor VDI was held to discuss the current interim report. Fortunately, the project is on schedule.

Grant number: 13XP5103A






Since the beginning of October Limedion is again certified according to the DIN EN ISO 9001 and DIN EN ISO 13485 standards. The repeat audit went off without any major deviations.


ISO 9001 and ISO 13485 certification at LiMedion





Personnel increase

Since September the company Limedion has additional support. Moritz Benner, development engineer in medical technology, now supports our team. A warm welcome.






Hagelstein, S.; Zankovic, S.; Kovacs, A.; Barkhoff, R.; Seidenstücker, M. Mechanical Analysis and Corrosion Analysis of Zinc Alloys for Bioabsorbable Implants for Osteosynthesis. Materials. 2022, 15, 421. [CrossRef]

This publication is about the research of new types of zinc-based alloys, such as zinc-silver (ZnAg) or zinc-silver-titanium-alloys (ZnAgTi) for osteosynthesis implants in terms of stability and resorbability. The mechanical values of the casted and extruded alloys were determined by tensile tests and the corrosion rates in PBS solution (phosphate-buffered solution) were investigated by electrochemical corrosion measurement. Zinc and its alloys exhibited favorable corrosion rates, especially compared to magnesium. Magnesium-based implants have a much slower rate of degradation and undesirable hydrogen gas pockets are formed during the process.

It could be shown that zinc-based alloys are very promising as a material for bioabsorbable orthopedic implants.




Hehrlein, C.; Schorch, B.; Haberstroh, J.; Bode, C.; Mey, L.; Schwarzbach, H.; Kinscherf, R.; Meckel, S.; Schiestel, S.; Kovacs, A.; Fischer H.; Nennig E. Bioresorbable zinc stent with ultra-thin center struts attenuates stent jail in porcine femoral artery bifurcations. Minimally Invasive Therapy & Allied Technologies 2020, 29, 72-79. [CrossRef]

This paper describes the research of an ultrathin and fracture-resistant stent, which is made of the bioresorbable material zinc. In addition, it has the property of a radiopaque region in the mid-region. Last but not least, it is characterized by extended and high fracture resistance. Zn stents and Zn drug-eluting-stents (DES) were implanted in both bifurcations of femoral arteries of 21 young pigs, observed for three months, and studied by angiography and histomorphometry. Both Zn-stents and Zn-DES could be precisely positioned in the bifurcation of the femoral artery. The openings of the side branches remained open after Zn stent deployment without blocking the stent.

Thus, it could be evaluated that a Zn stent with ultrathin middle struts may be useful for provisional stenting of vascular bifurcations.




Hehrlein, C.; Schorch, B.; Kress, N.; Arab, A.; v. z. Mühlen, C.; Bode, C.; Epting, T.; Haberstroh, J.; Mey, L.; Schwarzbach, H.; Kinscherf, R.; Stachniss, V.; Schiestel, S.; Kovacs, A.; Fischer, H.; Nennig E. Zn-alloy provides a novel platform for mechanically stable bioresorbable vascular stents. PLoS ONE, 2019, 14, 1-17. [CrossRef]

This publication includes the investigation of a ZnAg alloy for cardiovascular applications. As comparative materials, magnesium-based and PLLA stents, which are also bioresorbable, were investigated. Zinc alloys were found to be potentially more suitable for this application than the other two materials: magnesium often degrades prematurely, while PLLA has a mechanical stability which is sometimes too low. In the animal model, the investigated implants were illuminated with regard to thrombosis formation and restenosis formation. The mechanical properties of the ZnAg alloy are similar to the magnesium alloy in terms of tensile strength, but have a significantly higher elongation at fracture. The ZnAg alloy exhibits a superior outstanding X-ray visibility compared with the magnesium alloy. The platelet adhesion rate and hemocompatibility parameters showed no differences among the materials studied (ZnAg, PLLA, Mg, NiTi).

It was shown that the ZnAg alloy is a promising material platform for the fabrication of a new generation of bioresorbable vascular vascular stents.




On 2018-08-29 we have been granted a patent (EP 3 250 247 B1) with the following title:

Biodegradable alloy, production and use thereof, in particular for producing stents and other implant


Show LiMedion Patent


This patent is about the production of a biodegradable zinc-based alloy with a zinc content of 90.0-99.95 % and a silver content of 0.05-10.0%. This alloy is currently being used in a BMBF-funded research project by the company Optimed in which a biodegradable drug-eluting stent is being investigated.

In addition, this patent is used in the BMBF-funded research project Z-Bioresorb. That project is about a degradable bone pin, made of the mentioned alloy. In the event of a bone fracture, this pin only have to be inserted once into the patient. Explantation is not necessary, as the pin dissolves.